Navigation Links
NeurogesX Reports Fourth Quarter and Year-End 2008 Results
Date:3/20/2009

ented, "Our regulatory and commercialization timelines for Qutenza in the United States and Europe have remained on track. We have focused our cash resources on regulatory and pre-commercialization activities for Qutenza, deferring further clinical development of Qutenza, NGX-1998 and our preclinical prodrug development programs. Based on this conservative strategy, we believe we have sufficient cash runway through the anticipated timing of European Commission and FDA decisions, and through at least December 31, 2009. Potential proceeds received from our anticipated European commercial partnership, including upfront or near-term milestone payments, would be additive and have not been factored into our current cash forecast. With the potential for European and U.S. commercial partnerships, and other non-equity based sources of funding, we do not currently intend to raise equity capital in the public markets."

Development Update

NeurogesX' near-term focus is to secure regulatory approvals of the NDA and MAA for Qutenza. The CHMP's positive opinion recommending approval in the E.U. of Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain, was made in reliance on NeurogesX' commitment to conduct certain post-marketing studies. These post-marketing commitments, which are often required by the CHMP as a condition of an approval recommendation, may include an open-label safety study of Qutenza in on-label indications, as well as a clinical safety and efficacy study in painful diabetic neuropathy. These studies could potentially be conducted and/or funded by a European commercial partner, and the timing for initiating such studies will be provided following the European Commission's decision regarding final marketing authorization for Qutenza.

NGX-1998, the Company's second-generation, liquid formulation of the same active ingre
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
2. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
3. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
4. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
5. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
6. The NewsHour With Jim Lehrer Reports From South Africa on Renewed Efforts to Combat HIV/AIDS and Tuberculosis
7. Medical symposium highlights importance of case reports -- patient stories in modern medicine
8. Secova Reports Healthcare Provisions In The Stimulus Bill
9. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
10. Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results
11. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 Promising new research published in ... light on the potential ability of ketones to support ... The study shows that brain hypometabolism ... by impaired glucose uptake and/or utilization, and results suggest ... , The study, by the Research Center on Aging ...
(Date:9/17/2014)... September 16, 2014) A study led by ... the chemotherapy dose threshold below which male childhood ... production. The study appears in September 17 edition ... By clarifying which patients are at highest risk ... the findings to eventually increase use of pre-treatment ...
(Date:9/17/2014)... wine leads to an explosion of flavours in your mouth. ... that can mimic what happens in your mouth when you ... of dryness in the wine. , When wine growers turn ... of processes to bring out the desired flavour in the ... part of the taste is known in wine terminology as ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A  recent ... of a 24-year-old man named Advait Thakur who had ... caused by degenerative disc disease. This disease led to ... his nerve roots and causing severe pain. Leading spine ... and how it can lead to such severe pain, ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
Breaking Medicine News(10 mins):Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 3Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3
... that doctors in the US U.S. doctors often misdiagnose ... some patients to suffer for years.// ,Tuberculosis ... world, and according to the World Health Organization, has ... year 2004. A tuberculosis bacterium has the ability to ...
... be more effective at treating female alcoholics than traditional ... by researchers// at RTI International; University of Southern ... study, published in the Journal of Consulting and Clinical ... and their male partners who were not substance abusers. ...
... moms, suffer from stress urinary incontinence (SUI), a condition ... urine leakage.// ,“We try to treat patients ... doing Kegel exercises, and addressing problems such as chronic ... leakage worse,” says Andrew Sambell, M.D., a urologist on ...
... Postgraduate Medical Journal says that UK recommendations for the availability ... 1998, new legislation was introduced to limit the impact of ... in England and Wales. The drug is highly toxic to ... size of paracetamol packs available to a maximum of 32 ...
... a heart attack, according to new research from University ... the August edition of the journal Arthritis & Rheumatism ... ,http://www3.interscience.wiley.com/ cgibin/jhome/76509746, This is the first time that ... coronary heart disease could be at risk for heart ...
... conducted by the stem cells researchers across the world ... (BIMR)and Illumina Inc., it was found that embryonic stem ... and totipotent. ,This sets aside the embryonic ... cells. These characteristics could be later used to replace ...
Cached Medicine News:Health News:Doctors In US Lack Skills For The Diagnosis Of TB 2Health News:Marital Therapy Effective Treatment for Female Alcoholics 2Health News:UK Recommendations On Painkillers Flaunted 2Health News:Risk Of Heart Attack Increased By Gout 2Health News:Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning 2
(Date:9/17/2014)... LAUSANNE , Switzerland , ... part of Debiopharm Group ™ , is proud to ... ™ instrument. Debiopharm Diagnostics is a long-time ... portfolio. Idylla ™ Biocartis, fully ... designed to offer physicians fast and easy access ...
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes ... Million by the following Product Segments: SPECT Systems (Includes SPECT ... systems). The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:9/16/2014)... Sept. 16, 2014 3SBio Inc., ("3SBio") ... China focusing on researching, developing, manufacturing ... has entered into an exclusive license agreement with ... manufacturing and marketing in Mainland China of PEG-irinotecan, ... (Topo-I). Topo-I is over-expressed in many solid tumors, ...
Breaking Medicine Technology:Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 263SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
Bipolar gingivoplasty loop. Individual sterile packs....
The Hilan pneumatic high speed drill system consists of a pneumatic motor and drill with various cutting attachments....
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
Medicine Products: